 Provider News GeorgiaApril 2024 Provider Newsletter Contents
GABCBS-CRCM-053365-24 HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Effective for all claims received on and after May 1, 2024, Anthem is updating its outpatient facility editing system to align with correct coding guidelines. As a result, claims billed with HCPCS/CPT® codes 0373T, 0362T, 90853, 90887, 96121-96171, 97151-97158, 90785, 90791, 90792, 90832-90847, 90863, H0001-H2035, S0201, S9480, and an inappropriate revenue code(s) will be denied. For assistance with coding guidelines, please refer to CPT Coding Guidelines or Encoder Pro. If you believe you have received a denial in error, please follow the standard claim payment dispute process outlined in the provider manual. To access, visit anthem.com/provider and select Change State, then select Providers, Guidelines & Manuals. Finally, select Download the Manual under the Provider Manuals ribbon. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-052241-24 As previously noticed in our March 2020 provider newsletter tinyurl.com/mr3n9nw2, providers must code their claims to the highest level of specificity in accordance with industry standard coding guidelines, such as ICD-10-CM coding guidelines and reporting. When an ICD-10-CM diagnosis code has a specified anatomical laterality within the code description, the anatomical modifier that is appended to a CPT® or HCPCS code must correspond to the laterality within the ICD-10-CM description to identify different areas of the body that were treated. Proper application of the anatomical modifiers helps ensure the highest level of specificity on the claim and can help show that different anatomic sites received treatment. Professional claims submitted on a CMS 1500 form, for claims processed on or after May 1, 2024, Anthem will apply these correct coding ICD-10-CM guidelines and deny claim lines that have a laterality diagnosis submitted with a CPT or HCPC modifier that does not correspond to the diagnosis. These are some improper coding examples: - Reported diagnosis: E11.3593 (Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral)
Billed CPT code: 67228-RT Treatment of extensive or progressive retinopathy (for example, diabetic retinopathy), photocoagulation. Determination: It is not appropriate to report an RT modifier when the laterality of bilateral is identified in the ICD-10 diagnosis. Therefore, the claim line will be denied. - Reported diagnosis: S91.011A (Laceration without foreign body, right ankle, initial encounter)
Billed CPT code: 27786-LT (Closed treatment of distal fibular fracture: lateral malleolus; without manipulation) Determination: It is not appropriate to report an LT modifier when the laterality of right is identified in the ICD-10 diagnosis. Therefore, the claim line will be denied.
Additionally, the ICD-10-CM diagnosis code should correspond to the medical record, CPT,® HCPCS code(s), and/or modifiers billed. Anthem will continue to enhance its editing system to automate edits and simplify remittance messaging supported by correct coding guidelines. The enhanced editing automation will promote faster claim processing and reduce follow-up audits and/or record requests for claims not consistent with correct coding guidelines. If you have questions about this communication or need assistance, contact your provider relationship management representative. EOB message — Diagnosis codes with a specified laterality description should be submitted with the appropriate modifier of specificity and procedure code. Ex code: 00W19 With your help, we can continually build towards a future of shared success. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. GABCBS-CM-053655-24 Based on feedback from our care provider partners, we understand the majority prefer not to receive paper letters. We want to make our interactions easy through digital channels and ensure you receive authorization case notifications timely. Since notifications about authorization decisions are available today through Availity Essentials, we will soon eliminate sending paper notifications. You now have 24/7 access to authorization case information in one location through Availity Essentials. The digital authorization case status notifications are available under the Authorizations and Referrals* application once you have logged in to Availity Essentials and selected Patient Registration. By eliminating the redundancy of receiving both a digital and paper letter, you’ll see fewer errors associated with manual processes in handling the paper letters while reducing cost and our carbon footprint. * Note: Your Availity Essentials administrator must assign you the role of Authorization & Referral Inquiry or request to access this application. Care providers will be able to choose different options to receive authorization decision notifications via the Provider Preference Center under Availity Payer Spaces. Look for details on the Provider Preference Center options and ways to access authorization case status in an upcoming communication. We are focused on reducing administrative burdens, so you can do what you do best — care for our members. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-051377-24-CPN51281 Please review your online provider directory information on a regular basis to ensure it is correct. Access your online provider directory information by visiting anthem.com/provider, then at the top of the webpage, choose Find Care. Review your information and let us know if any of your information in our online directory has changed.
Updating your information
Anthem uses the provider data management (PDM) capability available on Availity Essentials to update your provider or facility data. Using the Availity PDM capability meets the quarterly attestation requirement to validate provider demographic data set by the Consolidated Appropriations Act (CAA).
PDM features include:
- Updating provider demographic information for all assigned payers in one location.
- Attesting to and managing current provider demographic information.
- Monitoring submitted demographic updates in real-time with a digital dashboard.
- Reviewing the history of previously verified data.
Accessing the PDM application
Log on to Availity.com and select My Providers > Provider Data Management to begin using PDM. Administrators will automatically be granted access to PDM. Additional staff may be given access to PDM by an administrator. To find your administrator, go to My Account Dashboard > My Account > Organization(s) > Administrator Information.
PDM training
PDM training is available:
- Learn about and attend one of our training opportunities by visiting here.
- View the Availity PDM quick start guide here.
- Roster automation standard template and roster automation rules of engagement specific training:
- Listen to our recorded webinar here.
Not registered for Availity Essentials yet?
If you aren’t registered to use Availity Essentials, signing up is easy and 100% secure. There is no cost for providers to register or to use any of our digital applications. Start by going to Availity.com and selecting New to Availity? Get Started at the top of the home screen to access the registration page. If you have more than one tax ID number (TIN), please ensure you have registered all TINs associated with your account.
If you have questions regarding registration, reach out to Availity Client Services at 800‑AVAILITY.
We are excited for genuine collaboration with you, our care provider partners. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-053040-24 Anthem uses post-pay and prepayment review in certain circumstances to validate the appropriate level for facility emergency department (ED) claims. This process identifies the level of ED E&M code by intensity and/or complexity of resources or interventions a facility uses to furnish all services indicated on the claim. Providers must use appropriate HIPAA-compliant codes for all services rendered during the ED encounter. The highest intervention/resource used will determine the final facility ED level. Anthem defines: - Interventions: the staff the facility uses and their work performed
- Resources: facility building, equipment, and/or supplies used
- Note: Professional provider services are not considered facility interventions or resources.
- Intensity and/or complexity: quantity, type, or specialization of interventions and/or resources used and the nature of the presenting problem, member age, acuity, and diagnostic services performed, as indicated on the claim
- Emergency services: a medical condition manifesting itself by acute symptoms of recent onset and sufficient severity (including severe pain) such that a prudent layperson, who possesses an average knowledge of health and medicine, could reasonably expect the absence of immediate medical care, could result in (a) placing the health of an individual in serious jeopardy, (b) serious impairment to bodily function, (c) serious dysfunction of any bodily organ or part, (d) serious disfigurement, or (e) in the case of a pregnant woman, serious jeopardy to the health of the woman or her unborn child
** In the event a determination cannot be made based on the guidance in this document, a referral to a medical director for a determination will be made. CPT® 99281/HCPCS G0380 Straight forward complexity | The presenting problem(s) are self-limited or minor conditions with no medications or home treatment required, signs and symptoms of wound infection explained, return to ED if problems develop. | Facility intervention | Clinical examples | Triage only | Insect bite (uncomplicated) | No medication or treatment | Read Tb test | Wound recheck | | Steri-Strip wound | | Booster or follow up immunization—no acute injury | | Dressing change (uncomplicated) | | Prescription refill | | Suture removal (uncomplicated) | |
CPT 99282/HCPCS G0381 Low complexity | The presented problem(s) are of low to moderate severity. Over the counter (OTC) medications or treatment, simple dressing changes; patient demonstrates understanding quickly and easily. | Facility intervention | Clinical examples | Simple trauma — up to one x-ray procedure | Localized skin rash, lesion, sunburn | Cast removal | Minor viral infection | Visual acuity exam (Snellen) | Eye discharge — painless | Basic specimen testing: Accucheck, dipstick, UA clean catch | Urinary frequency without fever | I&D of simple abscess | Ear pain (otitis media, sinusitis, vertigo, swimmer's ear, TMJ) | Venipuncture of lab | Dental pain | Simple cultures (throat, skin, urine, wound) | Epistaxis — no packing | Simple laceration/abrasion repair (with Dermabond, without sutures) | Assisting MD with any exam | Simple removal of foreign body without incision or anesthetic | | Apply ace wrap or sling | | Prep or assist with procedures such as minor laceration repair | | Simple burn treatment (first or second degree) | | OTC medication administered | | EKG | |
CPT 99283/HCPCS G0382 Moderate complexity | The presented problem(s) are of moderate severity. Head injury instructions, crutch training, bending, lifting, weight-bearing limitations, prescription medication with review of side effects and potential adverse reactions; patient may have questions, but otherwise demonstrates adequate understanding of instructions either verbally or by demonstration. | Facility intervention | Clinical examples | Nebulizer treatment (two or less) | Headache (simple) — history of, no serial exam | Oxygen therapy | Head injury - without neurologic symptoms | Access port catheter | Cellulitis | Heparin/saline lock | Abdominal pain (simple) | IV push medication | Minor trauma (with potential complicating factors) | IV fluids without medication | Medical conditions requiring prescription drug management | IM or Sub-Q medication administration | Fever which responds to antipyretics | Ear or eye irrigation | Eye pain (corneal abrasion or infection, blepharitis, iritis) | Foley catheter insertion | Non-confirmed overdose | Doppler assessment | Mental health — anxious, simple treatment | Prescription medication administer — PO | Mild dyspnea - not requiring oxygen | Fluorescein stain | Fissure or hemorrhoid | Prep or assist with procedures such as joint aspiration/injection, simple, fracture care, etc. | Epistaxis with packing | X-ray of two or more body areas or two or more x-ray procedures (not above and below joint of same limb) | Assault without radiological testing | | Psychotic patient with no imminent danger to self or others which includes social worker or behavioral health clearance. | | Emesis/Incontinence care | | Postmortem care | | Simple dislocation of patella, finger, or toes without fracture | | Sprain — unable to bear weight | | Routine trach care |
CPT 99284/HCPCS G0383 Moderate-high complexity | The presented problem(s) are of high severity and require urgent evaluation by the physician but do not pose an immediate significant threat to life or physiologic function. Head injury instructions, crutch training, bending, lifting, weight-bearing limitations, prescription medication with review of side effects and potential adverse reactions; patient may have questions, but otherwise demonstrates adequate understanding of instructions either verbally or by demonstration. | Facility intervention | Clinical examples | Blood transfusion | Headache — (complex) or with nausea and vomiting | Insertion of nasal/oral airway | Head injury with LOC | Special imaging study (CT, MRI, Ultrasound, VQ scan) | Chest pain (simple) or with limited diagnostic testing | Cardiac monitoring (external) | Respiratory distress | Administration and monitoring of infusion or parental medications (IV, IM, IO, SC) (Not for immunization administration) | Blunt/penetrating trauma with limited diagnostic testing | Insertion of NG or PEG tube placement, or replacement with multiple reassessments | Dehydration requiring treatment | Prep or assist with procedures such as” Irrigation of eye with Morgan lens, complex laceration repair | Dyspnea with oxygen treatment | Irrigation of bladder with three-way foley catheter | Neurological symptoms: slurred speech, staggered walking, paralysis or numbness of face, arm or leg, or blurred vision in one or both eyes | Change trach tube | Psychotic patient requiring medications in ED with no imminent danger to self or others | EKG x two or more | Care of a confused, combative patient | | Change in mental status of patient |
CPT 99285/HCPCS G0384 High complexity | The presented problem(s) are of high severity and pose an immediate significant threat to life or physiologic function. Multiple prescription medications and/or home therapies with review of side effects and potential adverse reactions; diabetic, seizure, or asthma teaching in compromised or non-compliant patients; patient/caregiver may demonstrate difficulty understanding instructions and may require additional directions to support compliance with prescribed treatment. | Facility intervention | Clinical examples | Cardiac monitoring (invasive) | Chest pain (cardiac) | Multiple IV administrations, does not include fluid administration, and at least one diagnostic imaging study with IV contrast. | Active GI bleed — excluding fissure and hemorrhoid | Physical or chemical restraints | Severe respiratory distress | Fracture reduction or relocation | Epistaxis (complex) | Endotracheal or trach tube insertion | Blunt/penetrating trauma with multiple diagnostic testing required | Endoscopy | Systemic multi-system medical emergency requiring multiple diagnostics | Thoracentesis or paracentesis | Severe infections requiring IV/IM antibiotics | Conscious sedation | Uncontrolled diabetes — blood sugar level at 300 or higher and exhibiting complications like DKA and or unstable vital signs or HHNK | Decontamination for isolation, hazardous material | Severe burns — (level 3 or 4) | Precipitous delivery in ER | Hypothermia | Nebulizer treatments — three or more (If Nebulizer is continuous, each 20-minute period is considered one treatment) | New onset altered mental status | PICC Insertion | Headache (severe) | Lumbar puncture | Major musculoskeletal injury | Sexual Assault Exam with specimen collection by ED staff | Acute peripheral vascular compromise of extremities | Coordination of hospital admission (inpatient or observation) or transfer or change in living situation or site | Toxic ingestions | More than one imaging study (CT, MRI, Ultrasound, VQ scan) combined with multiple different types of departmental tests (lab, EKG, x-ray) | Suicidal or homicidal patient with risk to self or others | Elevated D-dimer that leads to single special imaging study, for example, CT scan | Sexual assault exam with specimen collection | | Abdominal pain (complex) |
Reference and research material | Developed through the consideration of the American College of Emergency Physicians ED Facility Level Coding Guidelines. Revised: April 14, 2022 |
For specific administrative policy details, visit anthem.com/provider/forms and select your state. Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partners. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-052509-24 We strive to advance health equity so everyone has a fair opportunity to be at their healthiest. As we reduce barriers to whole health — physical, behavioral, and social — and personalize the healthcare journey, we can more effectively advance health equity. While focusing on understanding member needs, we actively develop educational tools for care providers. In recognition of the American Heart Association designating April as National Minority Health Month and Stress Awareness Month, we are featuring two Continuing Medical Education (CME) courses offered in a comprehensive repository of resources on My Diverse Patients. The site is designed to help care providers support the needs of diverse patients and address healthcare disparities. For the month of April, our featured eLearning experiences are: - Reducing Health Care Stereotype Threat — course benefits:
- Understand Health Care Stereotype Threat (HCST) and its implications for multicultural patient groups.
- Learn to recognize when patients may be experiencing HCST.
- Explore shifts that you can make to reduce the likelihood that patients from diverse groups will experience HCST.
- Identify the benefits of reducing HCST to both your patients and your practice.
- Medication Adherence — course benefits:
- Recognize potential barriers to medication adherence and what influences your patients’ thoughts and emotions.
- Understand the importance of meeting your patients where they are, and not where you want them to be.
- Learn how to navigate and break through barriers with C.A.R.E.
These courses are designed for: doctors (CME credit provided); nurses; health professionals; and medical office staff. Providers can view these courses on their smartphone, tablet, or computer. Through genuine collaboration, we can simplify access to care and help you deliver high-quality, equitable healthcare. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-ALL-CRCM-052988-24-CPN52169 Blue High Performance NetworkSM (BlueHPNSM) plans offer access to providers with a record of delivering high-quality, efficient care. Since January 2021, we’ve been collaborating with select healthcare providers across the U.S. to make BlueHPN available to members. Anthem’s mission is to provide affordable, quality healthcare benefits to its members. This in-network only plan helps keep members’ healthcare costs more predictable and manageable. It is important to know that only in-network care is covered in the BlueHPN. Members in the BlueHPN cannot go to out-of-network doctors or hospitals, except in an urgent and/or emergent situation. If they see a provider for routine or non-urgent care outside the BlueHPN, they will not have coverage. If you are not participating in the Blue Connection network, you are also not participating in the BlueHPN. Recognizing BlueHPN membersYou and your staff can identify patients enrolled in BlueHPN plans by their member ID card. The BlueHPN name will be prominently displayed on the front of the member ID card, along with the BlueHPN suitcase logo, as shown below: 
Eligibility and benefitsBlueHPN does not offer coverage for out-of-network care with the exception of urgent and/or emergent services. This means that BlueHPN patients will receive full benefits from in-network BlueHPN providers. You can check BlueHPN plan member eligibility and benefits the same way you do today for Blue Connection members — Either submit a HIPAA 270 eligibility and benefit request transaction or contact Provider Services at the number on the back of the member’s ID card. Referrals to BlueHPN providersBlueHPN is a comprehensive network that includes a full range of providers, from primary care doctors and specialists to hospitals. Not all healthcare providers are included. To ensure your BlueHPN patients will have full benefits when they need to see a specialist or another healthcare provider, it’s important that you only recommend other BlueHPN healthcare providers. You can use the Find a Doctor/Find Care tool at https://anthem.com/find-care to identify BlueHPN healthcare providers by searching by the member’s ID or alpha prefix. This will help ensure your patients will be receiving care from healthcare providers who are also committed to providing high quality, cost-efficient care. Please make sure you and your office staff are checking network status when referring members to new providers. Formal physician-to-physician referrals are not required under BlueHPN plans, but out-of-network benefits are limited to urgent and/or emergent services only. That means referrals for non-emergency care to providers outside the BlueHPN network, including durable medical equipment and laboratory services, may be costly for your patients. Additional network informationMore than 60 large metropolitan areas have their own high-performance networks sponsored by local Anthem plans across the country, which gives national employers access to high quality, cost-efficient providers in these geographic areas. The Georgia BlueHPN uses the existing Blue Connection network; therefore, you may see both local patients who have access to Blue Connection through the Anthem plan and patients traveling from other cities where BlueHPN products are offered. Georgia-based employer-sponsored health plans with access to our Georgia High Performance Network refer to the BlueHPN as Blue Connection. If you are not sure whether your practice is part of the Georgia BlueHPN or Blue Connection, ask your office manager or business office or contact your provider relationship account manager. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. GABCBS-CM-052010-24-CPN50889 When we receive a corrected claim and it doesn’t have the original claim number, or the original claim number is not correctly entered, we are not able to process it because we’re not able to connect it to the original claim. - For providers and their vendors (clearinghouses or billing services) submitting a corrected claim through EDI, we will send you a 277CA EDI Response Report acknowledging that we’ve received the submission, but are not able to process it:
- In this instance, you can either submit a new corrected claim with the original claim ID number or submit the corrected claim as an original claim if you do not have the original claim ID number.
- It is important that you submit proof of timely filing when resubmitting the correction or the original claim so we can ensure the claim is processed according to the timely filing guidelines.
- For providers using Claims Status application on Availity.com, you will not be able to access the corrected claim if it was rejected on the 277CA EDI Response Report:
- In this instance, you can either submit a new corrected claim with the original claim ID number or submit the corrected claim as an original claim if you do not have the original claim ID number.
- It is important that you submit proof of timely filing when resubmitting the correction or the original claim so we can ensure the claim is processed according to the timely filing guidelines.
We’ve also developed a training video that can help you reduce duplicate claims along with a training guide called Making the Claims Process Work for You to help you properly submit a corrected claim. Access the video and download the guide here. Provider information is required to view this training; however, you will only be prompted to enter this information the first time viewing this training. If you have questions about submitting a corrected claim, reach out to your provider representative or work with your EDI vendor to ensure you are receiving the 277CA Response Report. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-049145-23-CPN48099, MULTI-BCBS-CM-061597-24-CPN61590 Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. GABCBS-CM-052972-24 ATTACHMENTS (available on web): Medical Policy and Clinical Guideline updates 4/10/2024 (pdf - 0.29mb) The Medical Policies, Clinical Utilization Management (UM) Guidelines, and Third-Party Criteria below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed. Please share this notice with other providers in your practice and office staff. To view a guideline, visit anthem.com/medicareprovider and select Change State and pick appropriate state. Then Providers > Policies, Guidelines & Manuals. Notes/updates:Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive: - ANC.00009 - Cosmetic and Reconstructive Services of the Trunk, Groin, and Extremities;
- Previously titled: Cosmetic and Reconstructive Services of the Trunk and Groin:
- Revised title to include “Extremities"
- Revised Position Statement regarding lipectomy or liposuction for lymphedema and lipedema
- DME.00011 - Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices:
- Reformatted bullet points to letters
- Added lines to Investigational & Not Medically Necessary statement on electrical stimulation wound treatment device, electromagnetic wound treatment devices and pulsed electromagnetic field stimulation
- LAB.00011 - Selected Protein Biomarker Algorithmic Assays:
- Reformatted bullet points to letters
- Added IMMray® PanCan-d test to the Investigational & Not Medically Necessary statement
- LAB.00028 - Blood-based Biomarker Tests for Multiple Sclerosis, Previously titled: Serum Biomarker Tests for Multiple Sclerosis:
- Revised title
- Expanded scope of document from serum to blood-based biomarker testing for multiple sclerosis (MS)
- Revised Position Statement to indicate blood-based biomarker tests for multiple sclerosis are considered Investigational & Not Medically Necessary for all uses
- MED.00140 - Lentiviral Gene Therapy for Beta Thalassemia and Sickle Cell Disease; Previously Titled: Gene Therapy for Beta Thalassemia:
- Revised title
- Added Investigational & Not Medically Necessary statement on lovotibeglogene autotemcel
- MED.00144 - Gene Therapy for Duchenne Muscular Dystrophy:
- Outlines the Medically Necessary and Investigational & Not Medically Necessary criteria for the infusion of Delandistrogene moxeparvovec-rokl (ELEVIDYS)
- MED.00147 - Cellular Therapy Products for Allogeneic Stem Cell Transplantation:
- Outlines the Medically Necessary and Investigational & Not Medically Necessary criteria for the use of ex-vivo expansion of cord blood stem cell products
- SURG.00129 - Percutaneous Vertebral Disc and Vertebral Endplate Procedures:
- Removed the criteria examples for failed CPAP treatment
- Added definition for failed CPAP treatment
- SURG.00144 - Occipital and Sphenopalatine Ganglion Nerve Block Therapy for the Treatment of Headache and Neuralgia; Previously titled: Occipital Nerve Block Therapy for the Treatment of Headache and Occipital Neuralgia:
- Revised title
- Added Investigational & Not Medically Necessary statement for sphenopalatine ganglion nerve blocks
- TRANS.00041 - Histological Analysis using Microarray Gene Expression Profiling for Kidney Allograft Injury or Rejection:
- Histological analysis using microarray gene expression profiling is considered Investigational & Not Medically Necessary for detection of allograft injury or rejection in kidney transplant recipients
- CG-MED-39 - Bone Mineral Density Testing Measurement:
- Added phrase “using Dual-X-Ray Absorptiometry” to bullets I and III of Medically Necessary criteria and to bullets I and IV of Not Medically Necessary criteria
- Added Not Medically Necessary position statement for bone strength and fracture risk assessment using imaging scans other than DXA
- CG-MED-95 - Transanal Irrigation:
- Outlines the Medically Necessary and Not Medically Necessary criteria for transanal irrigation
- CG-OR-PR-05 - Myoelectric Upper Extremity Prosthetic Devices:
- Revised formatting of Medically Necessary section
- Added Repair and Replacement criteria to Clinical Indications section
- Added new Not Medically Necessary statement regarding enhanced dexterity prosthetic arm myoelectric upper extremity prosthetic devices
- Added new Medically Necessary and Not Medically Necessary criteria for device repair and replacement.
- CG-SURG-61 - Cryosurgical, Radiofrequency, Microwave or Laser Ablation to Treat Solid Tumors Outside the Liver; Previously titled: Cryosurgical, Radiofrequency or Laser Ablation to Treat Solid Tumors Outside the Liver:
- Revised title
- Added microwave ablation to the Clinical Indications
- Added cryoablation and microwave ablation to the Medically Necessary indications for NSCLC and malignant tumors that have metastasized to the lung
- Added Not Medically Necessary statements regarding focal cryoablation of the prostate and microwave ablation for all other indications
- Revised Medically Necessary indication for cryoablation of the prostate to whole gland cryoablation of the prostate
- Reordered clinical indications to be based on clinical condition rather than ablative technique
Medical PoliciesOn August 10, 2023, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Anthem. These medical policies take effect April 5, 2024. Publish date | Medical Policy number | Medical Policy title | New or revised | 9/27/2023 | *ANC.00009 | Cosmetic and Reconstructive Services of the Trunk, Groin, and Extremities Previously titled: Cosmetic and Reconstructive Services of the Trunk and Groin | Revised | 9/27/2023 | *DME.00011 | Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices | Revised | 9/27/2023 | *LAB.00011 | Selected Protein Biomarker Algorithmic Assays | Revised | 9/27/2023 | *LAB.00028 | Blood-based Biomarker Tests for Multiple Sclerosis Previously titled: Serum Biomarker Tests for Multiple Sclerosis | Revised | 9/27/2023 | *MED.00140 | Lentiviral Gene Therapy for Beta Thalassemia and Sickle Cell Disease Previously Titled: Gene Therapy for Beta Thalassemia | Revised | 9/27/2023 | *MED.00144 | Gene Therapy for Duchenne Muscular Dystrophy | New | 9/27/2023 | *MED.00147 | Cellular Therapy Products for Allogeneic Stem Cell Transplantation | New | 9/27/2023 | SURG.00052 | Percutaneous Vertebral Disc and Vertebral Endplate Procedures | Revised | 9/27/2023 | *SURG.00129 | Oral, Pharyngeal and Maxillofacial Surgical Treatment for Obstructive Sleep Apnea or Snoring | Revised | 9/27/2023 | *SURG.00144 | Occipital and Sphenopalatine Ganglion Nerve Block Therapy for the Treatment of Headache and Neuralgia Previously titled: Occipital Nerve Block Therapy for the Treatment of Headache and Occipital Neuralgia | Revised | 9/27/2023 | TRANS.00039 | Portable Normothermic Organ Perfusion Systems | Revised | 9/27/2023 | *TRANS.00041 | Histological Analysis using Microarray Gene Expression Profiling for Kidney Allograft Injury or Rejection | New |
Clinical UM GuidelinesOn August 10, 2023, the MPTAC approved the following Clinical UM Guidelines applicable to Anthem. These guidelines were adopted by the medical operations committee for Medicare Advantage members on September 28, 2023. These guidelines take effect April 5, 2024. Publish date | Clinical UM Guideline number | Clinical UM Guideline title | New or revised | 9/27/2023 | *CG-MED-39 | Bone Mineral Density Testing Measurement | Revised | 9/27/2023 | CG-MED-83 | Site of Care: Specialty Pharmaceuticals | Revised | 9/27/2023 | *CG-MED-95 | Transanal Irrigation | New | 9/27/2023 | *CG-OR-PR-05 | Myoelectric Upper Extremity Prosthetic Devices | Revised | 9/27/2023 | CG-OR-PR-08 | Microprocessor Controlled Lower Limb Prosthesis | Conversion New | 9/27/2023 | CG-OR-PR-09 | Microprocessor Controlled Knee-Ankle-Foot Orthosis | Conversion New | 9/27/2023 | CG-SURG-01 | Colonoscopy | Revised | 9/27/2023 | *CG-SURG-61 | Cryosurgical, Radiofrequency, Microwave or Laser Ablation to Treat Solid Tumors Outside the Liver Previously titled: Cryosurgical, Radiofrequency or Laser Ablation to Treat Solid Tumors Outside the Liver | Revised | 9/27/2023 | CG-SURG-79 | Implantable Infusion Pumps | Revised | 9/27/2023 | CG-SURG-83 | Bariatric Surgery and Other Treatments for Clinically Severe Obesity | Revised |
Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CR-049964-24-CPN49653 The following guideline was among those recently approved at the Medical Policy and Technology Assessment Committee meeting held on February 15, 2024. Revisions have been made to the coding, which may result in services previously considered medically necessary to now be considered not medically necessary for Date of Service (DOS) on or after July 1, 2024. Guideline | Code(s) | ANC.00008 Cosmetic and Reconstructive Services of the Head and Neck | 21086, L8045 |
We are committed to finding solutions that help our care provider partners offer quality services to our members. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. GABCBS-CM-052992-24 As communicated in the March 2024, provider newsletter, effective April 1, 2024, Carelon Medical Benefits Management, Inc., a specialty health benefits company, will expand multiple Carelon Medical Benefits Management programs to perform medical necessity reviews for additional procedures for Anthem members, as further outlined below. Carelon Medical Benefits Management works with leading insurers to improve healthcare quality and manage costs for today’s most complex and prevalent tests and treatments, helping to promote care that is appropriate, safe, and affordable. The expansion will require clinical appropriateness review for additional procedures related to the Carelon Medical Benefits Management Expanded Cardiology, Genetic Testing, Radiology, Musculoskeletal, Surgical, and Radiation Oncology programs. The clinical guidelines and medical policies that have been adopted by Anthem to be used for medical necessity review are in the table below. Carelon Medical Benefits Management will begin accepting prior authorization requests on March 18, 2024, for dates of service April 1, 2024, and after. Members included in the new programAll fully insured, self-funded (ASO), HealthLink, and national members currently participating in the Carelon Medical Benefits Management programs listed below are included. For self-funded (ASO) groups that currently do not participate in the Carelon Medical Benefits Management programs, the program will be offered to self-funded accounts (ASO) to add to their members’ benefit package as of April 1, 2024. A separate notice will be published for Medicare Advantage, Medicare, and MA GRS. Members of the following products are excluded: Medicaid, Medicare supplement, and Federal Employee Program® (FEP®). Pre-service review requirementsFor procedures that are scheduled to begin on or after April 1, 2024, all providers must contact Carelon Medical Benefits Management to obtain pre-service review for the services including but not limited to the following non-emergency modalities. Please refer to the clinical guidelines on the microsite resource pages for complete code lists. Please note: The procedure list has been updated since the original notification. All codes will only be reviewed for medical necessity for the requested service and not for site of care at this time. Vascular procedures will not require prior authorization for National and Commercial members currently participating in the Carelon Medical Benefits Management Cardiology program. Program | Services | Clinical Guidelines | Expanded Cardiology | - EPS studies
- Cardiac ablation
- Card monitor. device
- Cardiac contractility modulation
- Wearable cardioverter defibrillators
- Wireless CRT for left ventricular pacing
- PFO Closure devices
- Endovascular revascularization
- Cardiac Resynchronization Therapy
- Implantable Cardioverter Defibrillators
- Permanent Implantable Pacemakers
| - CG-MED-64
- CG-MED-74
- CG-SURG-55
- MED.00055
- SURG.00032
- SURG.00152
- SURG.00153
- THER-RAD.00012
- CAR07-0623.2
- CAR05-0423
- CAR06-0923.1
- CAR08-1023.2
| Genetic Testing | - Somatic Tumor Testing
- Chromosomal Microarray Analysis
- Pharmacogenomic Testing
- Carrier Screening in the Prenatal Setting and Preimplantation Genetic Testing
- Cell-free DNA Testing for the Management of Cancer
- Genetic Testing for Inherited Conditions
- Hereditary Cancer Testing
- Polygenic Risk Scores
- Prenatal Tesing using cell-free DNA
- Whole Exome Sequencing and Whole Genome Sequencing
| - GEN02-0324.1
- GEN07-0223.1
- GEN09-0223.1
- GEN05-0124.1
- GEN03-0124.1
- GEN06-0124.1
- GEN01-1123.2
- GEN10-0124.1
- GEN04-1123.3
| Radiology | - Radiostereormetric analysis
- Quantitative ultrasound for tissue characterization
- Myocardial sympathetic innervation & imaging w/wo spect.
- Lumbar discography
| - CG-SURG-29
- RAD.00064
- RAD.00065
- RAD.00067
| Musculoskeletal | - Extraosseous subtalar joint imp & arthroereisis
- Genicular Nerve block & ablation- CHR knee pain
- Percutaneous & Endo spinal surgery
- Implanted devices for Spinal stenosis
- Percutaneous vert disc & Endplate procedures
- Cryoablation for podiatric conditions
| - SURG.00052
- SURG.00071
- SURG.00092
- SURG.00100
- SURG.00104
- SURG.00142
| Surgical | - Wireless capsule endoscopy
- Paraoesophageal hernia repair
- Ablation proc. – tx of Barrett’s esophagus
- Transendoscopic Therapy for GE reflux / Dysphagia / gastroparesis
- Lower Esophageal sphincter augmentation devices
| - CG-SURG-92
- CG-SURG-101
- MED.00090
- SURG.00047
- SURG.00131
|
To determine if prior authorization is needed for a member on or after April 1, 2024, contact the Provider Services phone number on the back of the member’s ID card for benefit information. Providers using the Interactive Care Reviewer (ICR) tool on Availity Essentials to pre-certify an outpatient procedure will receive a message referring the provider to Carelon Medical Benefits Management. (Note: ICR cannot accept prior authorization requests for services administered by Carelon Medical Benefits Management.) Providers should continue to submit pre-service review requests to Carelon Medical Benefits Management using the convenient online service via the Carelon Medical Benefits Management ProviderPortal. ProviderPortal is available 24 hours a day, seven days a week, processing requests in real-time using Clinical Criteria. Go to providers.carelonmedicalbenefitsmanagement.com/ to register. For more informationGo to https://providers.carelonmedicalbenefitsmanagement.com/genetictesting, https://providers.carelonmedicalbenefitsmanagement.com/cardiology/, https://providers.carelonmedicalbenefitsmanagement.com/radiology/, https://providers.carelonmedicalbenefitsmanagement.com/musculoskeletal/, https://providers.carelonmedicalbenefitsmanagement.com/surgicalprocedures/; for resources to help your practice get started with the Radiology, Expanded Cardiology, Genetic Testing, Musculoskeletal, Surgical, and Radiation Oncology programs. Our special websites help you learn more and access helpful information and tools such as order entry checklists, clinical guidelines, and FAQs, or you can call your local Network Relations representative. With your help, we can continually build towards a future of shared success. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-053342-24 Effective for dates of service on and after July 1, 2024, the following codes will require prior authorization through Carelon Medical Benefits Management, Inc.: CPT® code | Description | 0403U | Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch post-digital rectal examination urine (or processed first-catch urine), algorithm reported | 0411U | Psychiatry (for example, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication | 0419U | Neuropsychiatry (for example, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype | 0262U | Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffin-embedded (FFPE) | 0405U | Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected | 0409U | Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number | 0410U | Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected | 0413U | Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow | 0414U | Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1 | 0417U | Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene |
As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon Medical Benefits Management in one of several ways: - Access Carelon Medical Benefits Management’s ProviderPortalSM directly at providerportal.com:
- Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.
- Access the Availity website at Availity.com.
If you have questions related to guidelines, please contact Carelon Medical Benefits Management via email at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may access and download a copy of the current and upcoming guidelines here. Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CRCM-051640-24-CPN51333 This article was previously posted with archived criteria CG-SURG-27 which has been removed. Previous article here. The following services will be added to precertification for the effective dates listed below. Eligibility and benefits can be verified by accessing Availity Essentials (Availity.com) or by calling the number on the back of the member’s identification card. Service precertification is based on member’s benefit plan/eligibility at the time the service is reviewed/approved. Benefit plans vary widely and are subject to change based on the contract effective dates. The provider is responsible for verification of member eligibility and covered benefits. Except in the case of an emergency, failure to obtain precertification prior to rendering the designated services listed below may result in denial of reimbursement. Add to precertification | Criteria | Criteria description | Code | Effective date | CG-SURG-88 | Mastectomy for Gynecomastia | 19300 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 33880 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 33881 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 33883 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 33886 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 33889 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 33891 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 34701 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 34702 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 34703 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 34704 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 34706 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 34710 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 34712 | 12/01/2023 | CG-SURG-78 | Locoregional Techniques for Treating Primary and Metastatic Liver Malignancies | 47120 | 12/01/2023 | CG-SURG-78 | Locoregional Techniques for Treating Primary and Metastatic Liver Malignancies | 47122 | 12/01/2023 | CG-SURG-78 | Locoregional Techniques for Treating Primary and Metastatic Liver Malignancies | 47125 | 12/01/2023 | CG-SURG-78 | Locoregional Techniques for Treating Primary and Metastatic Liver Malignancies | 47130 | 12/01/2023 | CG-SURG-89 | Radiofrequency Neurolysis and Pulsed Radiofrequency Therapy for Trigeminal Neuralgia | 61790 | 12/01/2023 | CG-SURG-89 | Radiofrequency Neurolysis and Pulsed Radiofrequency Therapy for Trigeminal Neuralgia | 61791 | 12/01/2023 | CG-SURG-89 | Radiofrequency Neurolysis and Pulsed Radiofrequency Therapy for Trigeminal Neuralgia | 64600 | 12/01/2023 | CG-SURG-89 | Radiofrequency Neurolysis and Pulsed Radiofrequency Therapy for Trigeminal Neuralgia | 64605 | 12/01/2023 | CG-SURG-89 | Radiofrequency Neurolysis and Pulsed Radiofrequency Therapy for Trigeminal Neuralgia | 64610 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 75956 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 75957 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 75958 | 12/01/2023 | CG-SURG-86 | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection | 75959 | 12/01/2023 | CG-DME-45 | Ultrasound Bone Growth Stimulation | E0760 | 12/01/2023 | CG-DME-06 | Compression Devices for Lymphedema | K1024 | 12/01/2023 | CG-DME-06 | Compression Devices for Lymphedema | K1025 | 12/01/2023 |
Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. GABCBS-CM-050237-24-SRS49080 Effective July 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem for Medicare Advantage members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines (including definitions and specific contract provisions/exclusions), take precedence over these precertification rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Description | 0088U | Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection Molecular Microscope® MMDx—Kidney, Kashi Clinical Laboratories | 0342U | Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline | 0361U | Neurofilament light chain, digital immunoassay, plasma, quantitative Neurofilament Light Chain (NfL), Mayo Clinic, Mayo Clinic | 0390U | Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-binding protein 4 (RBP4), by immunoassay, serum, algorithm reported as a risk score PEPredictDx, OncoOmicsDx Laboratory, mProbe | 0407U | Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function IntelxDKD™, Renalytix Inc, Renalytix Inc, NYC, NY | 0412U | Beta amyloid, Aβ42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology PrecivityAD® blood test, C2N Diagnostics LLC, C2N Diagnostics LLC | 0494T | Surgical preparation and cannulation of marginal (extended) cadaver donor lung(s) to ex vivo organ perfusion system, including decannulation, separation from the perfusion system, and cold preservation of the allograft prior to implantation, when performed | 0495T | Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (for example, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; first two hours in sterile field | 64505 | Injection, anesthetic agent; sphenopalatine ganglion [when specified as a therapeutic nerve block] |
Not all PA requirements are listed here. Detailed PA requirements are available to providers on anthem.com/medicareprovider on the Resources tab or for contracted providers by accessing Availity.com. Providers may also call Provider Services at the number on the back of the patient’s member ID card for assistance with PA requirements. UM AROW A2023M0970 Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CR-049933-24-CPN49553 This article was updated as of May 8, 2024. Beginning with dates of service on or after July 1, 2024, Anthem will update the Virtual Visits — Professional and Facility reimbursement policy in response to the conclusion of the federal public health emergency (PHE). The policy will be updated to indicate the following: - Virtual visits billed by professional providers are eligible for reimbursement for the following services:
- Audio and visual
- Audio only
- Asynchronous
- Store and forward
- Remote patient monitoring
- Virtual visits billed by facility providers are eligible for reimbursement for the following services:
- Audio and visual
- Audio only
- Originating site fee Q3014 only when the member is present
Any service identified as a virtual visit will be reimbursed at the office-based rate. For specific policy details, visit the reimbursement policy page at anthem.com. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-053089-24-SRS52932 Effective for dates of service on and after July 1, 2024, the specialty Medicare Part B drugs listed in the table below will be included in our precertification review process. Federal and state law, as well as state contract language and CMS guidelines (including definitions and specific contract provisions/exclusions), take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims. HCPCS or CPT® codes | Medicare Part B drugs | J3490, J3590, J9999, C9399 | Elrexfio (elranatamab-bcmm) | J3490, J3590 | Eylea HD (aflibercept) | J3490, J3590 | Pombiliti (cipaglucosidase alfa-atga) | J3490, J3590, J9999, C9399 | Talvey (talquetamab-tgvs) | J3490, J3590 | Tyruko (natalizumab-sztn) | J3590, C9399 | Veopoz (pozelimab-bbfg) | J3490 | Ycanth (cantharidin) |
Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CR-054037-24-CPN53511 Only Electronic Clinical Data Systems (ECDS) reporting will be used for this measure. Measure descriptionThe percentage of members 45 to 75 years of age who had appropriate screening for colorectal cancer (revised the age range from 50 to 75 years of age to 45 to 75 years of age). What we are looking for in provider recordsDocumentation in the medical record indicating the date when the colorectal cancer screening was performed and result or finding of one or more of the following: - A pathology report that indicates the type of screening (for example, colonoscopy, flexible sigmoidoscopy) and the date the screening was performed
- Documentation of a Fecal Occult Blood Test (FOBT) during the measurement year (2024)
- Documentation of a flexible sigmoidoscopy during the measurement year or the four years prior to the measurement year (January 1, 2020, to December 31, 2024)
- Documentation of a colonoscopy during the measurement year or the nine years prior to the measurement year (January 1, 2015, to December 31, 2024)
- Documentation of a CT colonography during the measurement year or the four years prior to the measurement year (January 1, 2020, to December 31, 2024)
- Documentation of Stool DNA (sDNA) with FIT test during the measurement year or two years prior to the measurement year (January 1, 2022, to December 31, 2024)
- Documentation of members who are diagnosed with colorectal cancer on or before December 31, 2024
- Documentation of a total colectomy on or before December 31, 2024 (documentation must state total, not partial)
- Evidence of hospice services in 2024
- Evidence patient expired prior to January 1, 2025
Helpful hints:- Recommend colorectal cancer screening to all patients 45 to 75 years of age.
- If a patient is hesitant, discuss different screening options.
- Educate that screening is recommended, even if there is no family history of colon cancer.
HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CRCM-050289-24-CPN49873 |